Evidence map›Paper›PMID 37308683›Full record

ArticlePediatric research2023

Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile.

Athena N Nguyen, Alec L Plotkin, Oludare A Odumade, Lesley De Armas, Savita Pahwa, Elena Morrocchi, Nicola Cotugno, Paolo Rossi, Caroline Foster, Sara Domínguez-Rodríguez and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 20 institutions in 10 countries.

Athena N Nguyen *Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Alec L Plotkin *Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Oludare A OdumadePrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Lesley De ArmasDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Savita PahwaDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Elena MorrocchiClinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Nicola CotugnoClinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paolo RossiDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Caroline FosterDepartment of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK.
Sara Domínguez-RodríguezFundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.
Alfredo TagarroFundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.
Caitlin SyphursPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Joann Diray-ArcePrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Benoit FatouDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Al OzonoffPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Ofer LevyPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Paolo Palma *Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. paolo.palma@opbg.net.
Kinga K Smolen *Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA. kinga.smolen@childrens.harvard.edu.ORCID http://orcid.org/0000-0001-8650-3693
on the behalf of the EPIICAL Consortium
Boston Children's Hospital · USPENTA Foundation · ITBambino Gesù Children's Hospital · ITManhiça Health Research Centre · MZUniversity of Rome Tor Vergata · ITBroad Institute · USColumbia University · USFundação Ariel Glaser Contra o SIDA Pediátrico · MZGianni Benzi Pharmacological Research Foundation · ITResearch Institute Hospital 12 de Octubre · ESUniversity College London · GBUniversity of Bamako · MLUniversity of Miami · USUniversity of the Witwatersrand · ZAUtrecht University · NLAfrica Health Research Institute · ZABarcelona Institute for Global Health · ESBrigham and Women's Hospital · USChulalongkorn University · THHospital General Universitario Gregorio Marañón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe long-term immunologic effects of antiretroviral therapy (ART) in children with perinatally-acquired HIV (PHIV) have not been fully elucidated. Here, we investigated how the timing of ART initiation affects the long-term immune profile of children living with PHIV by measuring immunomodulatory plasma cytokines, chemokines, and adenosine deaminases (ADAs).

methods40 PHIV participants initiated ART during infancy. 39 participant samples were available; 30 initiated ART ≤6 months (early-ART treatment); 9 initiated ART >6 months and <2 years (late-ART treatment). We compared plasma cytokine and chemokine concentrations and ADA enzymatic activities between early-ART and late-ART treatment 12.5 years later and measured correlation with clinical covariates.

resultsPlasma concentrations of 10 cytokines and chemokines (IFNγ, IL-12p70, IL-13, IL-17A, IL-IRA, IL-5, IL-6, and IL-9 as well as CCL7, CXCL10), ADA1, and ADA total were significantly higher in late-ART compared to early-ART treatment. Furthermore, ADA1 was significantly positively correlated with IFNγ, IL-17A, and IL-12p70. Meanwhile, total ADA was positively correlated with IFNγ, IL-13, IL-17A, IL-1RA, IL-6, and IL-12p70 as well as CCL7.

conclusionsElevation of several pro-inflammatory plasma analytes in late-ART despite 12.5 years of virologic suppression compared to early-ART treatment suggests that early treatment dampens the long-term plasma inflammatory profile in PHIV participants. IMPACT: This study examines differences in the plasma cytokine, chemokine, and ADA profiles 12.5 years after treatment between early (≤6months) and late (>6 months and <2 years) antiretroviral therapy (ART) treatment initiation in a cohort of European and UK study participants living with PHIV. Several cytokines and chemokines (e.g., IFNγ, IL-12p70, IL-6, and CXCL10) as well as ADA-1 are elevated in late-ART treatment in comparison to early-ART treatment. Our results suggest that effective ART treatment initiated within 6 months of life in PHIV participants dampens a long-term inflammatory plasma profile as compared to late-ART treatment.

Indexed as

HIV InfectionsAnti-Retroviral AgentsChemokinesChildCytokinesFemaleHumansInterleukin-13Interleukin-17Interleukin-6PregnancyAnti-Retroviral AgentsChemokinesCytokinesInterleukin-13Interleukin-17Interleukin-6

Identifiers

PMID37308683
OpenAlexW4380423025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.